Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Epidemiology of Thrombotic Thrombocytopenia Syndrome in Integrated Health-care Database in EnglandCompleted
NCT05222750N/AUpdated Dec 11, 2023
Sponsor: AstraZeneca
COVID-19
United Kingdom
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy ParticipantsCompleted
NCT05848440Phase 1Updated Dec 11, 2023
Sponsor: AstraZeneca
Non-alcoholic Steatohepatitis
United Kingdom
Study of DS-8201a for Participants With Advanced Solid Malignant TumorsCompleted
NCT03383692Phase 1Updated Dec 11, 2023
Sponsor: Daiichi Sankyo Co., Ltd.
Neoplasm Metastasis
Japan, South Korea, Taiwan
Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal CancerCompleted
NCT02870920Phase 2Updated Dec 8, 2023
Sponsor: Canadian Cancer Trials Group
Colorectal Cancer
Canada
Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers..Completed
NCT05955183Phase 1Updated Dec 8, 2023
Sponsor: AstraZeneca
Healthy Participants
United States
C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer PopulationCompleted
NCT02503436N/AUpdated Dec 4, 2023
Sponsor: AstraZeneca
Ovarian Cancer, Hereditary Ovarian Cancer Syndrome
Germany
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy AdherenceUnknown
NCT04663100NAUpdated Dec 4, 2023
Sponsor: University of Tennessee
Chronic Myeloid Leukemia · Chronic Lymphocytic Leukemia · Multiple Myeloma · Multiple Chronic Conditions
United States
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With HyperfiltrationCompleted
NCT02911792Phase 4Updated Nov 30, 2023
Sponsor: The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Type 2
United States
Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human HeartCompleted
NCT01798992Phase 4Updated Nov 29, 2023
Sponsor: University of Colorado, Denver
Idiopathic Dilated Cardiomyopathy
United States
Benralizumab Patient Access Programme Study: Retrospective Study in UK Severe Asthma CentresCompleted
NCT05932849N/AUpdated Nov 28, 2023
Sponsor: AstraZeneca
Asthma
United Kingdom
The National Register of Antipsychotic Medication in Pregnancy (NRAMP)Unknown
NCT00686946N/AUpdated Nov 28, 2023
Sponsor: The Alfred
Pregnancy · Mental Disorders
Australia
Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major BleedCompleted
NCT05548777N/AUpdated Nov 28, 2023
Sponsor: AstraZeneca
Anticoagulant-related Major Bleed
United States
Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney ImpairmentCompleted
NCT02923947Phase 1Updated Nov 27, 2023
Sponsor: AstraZeneca
Solid Tumours
France, South Korea, Spain
A Safety Study of AZD4041 in Healthy ParticipantsCompleted
NCT05233085Phase 1Updated Nov 27, 2023
Sponsor: AstraZeneca
Opioid Use Disorder (OUD)
Canada
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene AlterationsCompleted
NCT03448718Phase 2Updated Nov 22, 2023
Sponsor: Matthew Galsky
Metastatic Urothelial Cancer
United States
Osimertinib for NSCLC With Uncommon EGFR MutationsSuspended
NCT05421936N/AUpdated Nov 22, 2023
Sponsor: Sheba Medical Center
Carcinoma, Non-Small-Cell Lung · Genes, erbB-1
Israel
Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLCCompleted
NCT04105153N/AUpdated Nov 22, 2023
Sponsor: Thoraxklinik-Heidelberg gGmbH
EGFR Positive Non-small Cell Lung Cancer
Germany
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in AdultsCompleted
NCT04625972Phase 3Updated Nov 21, 2023
Sponsor: AstraZeneca
COVID-19
United States, United Kingdom
Oxford/AstraZeneca COVID-19 Vaccine Effectiveness in EnglandCompleted
NCT05047822N/AUpdated Nov 18, 2023
Sponsor: AstraZeneca
Covid-19 Infection
United Kingdom
A Study of Benralizumab in Patients With Eosinophilic EsophagitisTerminated
NCT04543409Phase 3Updated Nov 18, 2023
Sponsor: AstraZeneca
Eosinophilic Esophagitis
United States, Canada, France, Germany, Israel +7 more
Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell CanerTerminated
NCT03618134Phase 1, Phase 2Updated Nov 18, 2023
Sponsor: Jonsson Comprehensive Cancer Center
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8 · Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Human Papillomavirus Positive
United States
Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised ChildrenCompleted
NCT04484935Phase 2Updated Nov 15, 2023
Sponsor: AstraZeneca
RSV Infection
United States, Belgium, Japan, Poland, South Africa +3 more
Study of Tremelimumab in Patients With Advanced Solid TumorsCompleted
NCT02527434Phase 2Updated Nov 15, 2023
Sponsor: AstraZeneca
Urothelial Bladder Cancer · Triple-negative Breast Cancer · Pancreatic Ductal Adenocarcinoma
United States, Belgium, Netherlands, Poland, South Korea
Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.Completed
NCT01972217Phase 2Updated Nov 14, 2023
Sponsor: AstraZeneca
Metastatic Castration-resistant Prostate Cancer
United States, Belgium, Canada, Czechia, France +6 more
A Bioavailability and Food Effect Study of AZD5462 in Healthy VolunteersCompleted
NCT05512806Phase 1Updated Nov 9, 2023
Sponsor: AstraZeneca
Healthy Participants
United States

Previous page Next page